MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment
- MangoRx launches 'PRIME' with FDA-approved oral TRT treatment
- Targeting men with low testosterone seeking alternative TRT options
- Addressing a market of approximately 5,000,000 men on TRT therapy in the US
- Offering non-invasive oral therapy as an alternative to injectables
- Plans to collaborate with social media influencers and celebrities for PRIME's launch
- Expanding into a new vertical with massive market potential and little competition
- None.
Insights
The entry of Mangoceuticals, Inc.'s oral testosterone replacement therapy (TRT), PRIME, into the telehealth market represents a strategic move to capture a share of a growing market. With an estimated 5 million men in the U.S. currently on some form of TRT, the introduction of an oral option could disrupt traditional TRT methods. The convenience and non-invasive nature of an oral treatment, coupled with a significant potential user base averse to needles, positions PRIME to capitalize on unmet needs within the TRT space.
Moreover, the company's marketing strategy to leverage social media influencers and celebrities could enhance brand visibility and consumer trust. Given the company's established telemedicine infrastructure, the product's launch is likely to benefit from a streamlined distribution process, potentially resulting in rapid market penetration. However, the success of PRIME will depend on its ability to distinguish itself from competitors and demonstrate superior efficacy and safety profiles.
PRIME's FDA approval is a significant milestone, indicating that it has met the necessary safety and efficacy standards for oral testosterone therapies. This approval may also facilitate increased patient access to TRT by offering a treatment modality that is more acceptable to those with needle aversion. The clinical implications of an oral TRT could include improved patient adherence and satisfaction due to the ease of administration.
It is important to monitor post-marketing surveillance data to ensure that the reduced side effects claimed by PRIME compared to injectable TRT are substantiated in a real-world setting. The impact of this new therapy on patient outcomes and quality of life will be a critical factor in its long-term success in the market.
The introduction of PRIME by MangoRx may have positive financial implications for the company, given the sizable market for TRT treatments. The stock market often reacts favorably to product launches, especially when they address a substantial and underserved market segment. MangoRx's decision to enter the oral TRT market could potentially drive revenue growth and improve the company's market position.
Investors will be keen on observing the company's quarterly financials following PRIME's launch to gauge consumer adoption rates and revenue impact. It is also important to evaluate the cost-effectiveness of PRIME in comparison to existing TRT options, as this will influence both insurer coverage decisions and consumer choice.
The Dallas Based, Direct-to-Consumer Telemedicine Company Brings the FDA-Approved Oral Testosterone Replacement Therapy Treatment to the Telehealth Market
Dallas, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce the highly anticipated release and availability of ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ (“PRIME”) bringing the FDA-approved oral testosterone replacement therapy (TRT) treatment to consumers across the U.S via its proprietary telehealth platform.
MangoRx intends to market PRIME to those male individuals who are both a) currently on some alternative form of TRT treatment, such as topicals and other invasive injectables or pellets, and b) those experiencing common symptoms associated with low testosterone (Low-T) and seeking an immediate TRT treatment. Those interested in speaking with a medical provider to obtain a prescription for PRIME can do so by visiting MangoRx’s website at https://www.mangorx.com/app/prime.
According to a study published in the National Library of Medicine which examined prescribing patterns in the United States, approximately
Furthermore, the introduction of oral testosterone therapy presents a compelling opportunity to tap into a significant addressable market. By offering an alternative to injectable TRT, oral therapy addresses the concerns of individuals who are hesitant or unwilling to undergo injections. This segment of the market, encompassing those with needle aversion, represents a substantial portion of the population and presents a compelling case for the viability and potential growth of oral testosterone therapy.
Jacob Cohen, MangoRx’s Co-Founder and CEO, noted, “We firmly believe that between the convenience and non-invasive factor of taking PRIME orally and the reduced side effects that come with it as opposed to traditional injectable TRT, MangoRx is very well positioned to grab a significant piece of the current market share for men experiencing Low-T. As we believe PRIME’s oral delivery TRT treatment is a true game-changer, MangoRx will be seeking to engage popular social media influencers as well as high-profile celebrities and athletes to assist us as we launch PRIME into the marketplace.”
PRIME represents a critical expansion into a new vertical with massive market potential and very little competition on the consumer side, while remaining completely consistent with MangoRx’s established identity as a company committed to providing new and innovative pharmaceutical based solutions helping men achieve optimal performance in all areas of life. With the Company’s established marketing and telemedicine infrastructure in place, MangoRx is hitting the ground running to take PRIME to patients in need across the country. All orders will be reviewed and, pending approval, fulfilled, then discreetly shipped via MangoRx’s URAC accredited mail order partner pharmacy directly to the patient’s doorstep.
About PRIME
‘PRIME’, by MangoRx, powered by Kyzatrex®️, an innovative FDA-approved oral Testosterone Replacement Therapy (TRT) product, is a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions and is one of only three FDA approved TRT treatments that is delivered orally--as opposed to the traditional, invasive, and inconvenient injection-based drug delivery protocol. ‘PRIME’, by MangoRx, powered by Kyzatrex®️ delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.
The benefits of ‘PRIME,’ powered by Kyzatrex®️, over traditional injectable TRTs include enhanced vitality, improved mood, sharper cognition, optimized physical performance, and balanced hormonal levels at
To learn more about PRIME, please visit https://www.mangorx.com/app/prime for more information.
About MangoRx
MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.
To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.
Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 ("forward-looking statements"). These forward-looking statements represent the Company's current expectations or beliefs concerning future events and can generally be identified using statements that include words such as "estimate," "expects," "project," "believe," "anticipate," "intend," "plan," "foresee," "forecast," "likely," "will," "target" or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company's control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, but not limited to; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration ("FDA") and have not had the benefit of the FDA's clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA Act") provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen and President, Jonathan Arango, combined have majority voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; the fact that we have a significant number of outstanding warrants to purchase shares of common stock at
More information on potential factors that could affect the Company's financial results is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the Quarter ended September 30, 2023. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial
FOR PUBLIC RELATIONS
Lucky Break Public Relations
Sahra Simpson
Sahra@luckybreakpr.com
(323) 602-0091 ext. 704
FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com
MEDIA CONTACT
PHOENIX MGMT Marketing & Consulting
info@phoenix-mediamarketing.com
SOURCE: Mangoceuticals Inc.
FAQ
What is the ticker symbol for Mangoceuticals, Inc.?
What is 'PRIME' by MangoRx?
How can individuals obtain a prescription for PRIME?
What percentage of men aged over 40 have been prescribed with some form of TRT?
What marketing strategy will MangoRx employ for PRIME's launch?
